

Volume contents

Volume 6, Number 1, 1995

- 1 **Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxypyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1**
S. Massa, A. Mai, M. Artico, G. Sbardella, E. Tramontano, A.G. Loi, P. Scano & P. La Colla
- 9 **Antiviral activity of N⁴-aminocytidine derivatives related to AZT**
D. Loakes, D.M. Brown, N. Mahmood, J. Balzarini & E. De Clercq
- 17 **Inhibition of infection of T-cells with human immunodeficiency virus type 1 by dideoxynucleosides conjugated with oligopeptides**
N. S. Shimizu, A. Handa, N. G. Shimizu, R. Ikeda, T. Uchiyama, K. Achiwa & H. Hoshino
- 25 **The X-ray crystal structure of the sulfonated azo dye Congo Red, a non-peptidic inhibitor of HIV-1 protease which also binds to reverse transcriptase and amyloid proteins**
W. H. Ojala, C. R. Ojala & W. B. Gleason
- 34 **Potent inhibition of herpes simplex virus by MDL 101028, a novel biphenyl disulfonic acid urea co-polymer**
S. P. Ahmed, A. D. Cardin, C. G. Bridges, R. L. Jackson, M. J. Mullins & A. S. Tyms
- 43 **Synthesis and anti-HIV evaluation of alkyl and alkoxyethyl phosphodiester AZT derivatives**
T. Calogeropoulou, M. Koufaki, A. Tsotinis, J. Balzarini, E. De Clercq & A. Makriniannis
- 50 **The use of 5'-phosphate derivatives of nucleoside analogues as inhibitors of HIV-1 replication**
U. Nillroth, L. Vrang, G. Ahisén, Y. Besidsky, J. Chattopadhyaya, I. Ugi & U. H. Danielson
- 65 **Peptides containing 2-,3- or 4-fluorophenyl-alanine or 2,2- or 3,3-difluorophenylalanine as potential inhibitors of HIV protease**
S. Viani, R. Condom, P. R. T. Frogier & R. Guedj

Volume 6, Number 2, 1995

- 73 **Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442**
M. Seki, Y. Sadakata, S. Yuasa & M. Baba
- 80 **Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors**
R. W. King, S. Garber, D. L. Winslow, C. Reid, L. T. Bachelier, E. Anton & M. J. Otto

- 89 **A comparative study of the *in vitro* and *in vivo* antiviral activities of acyclovir and penciclovir**
P. Ertl, W. Snowden, D. Lowe, W. Miller, P. Collins & E. Littler
- 98 **Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor**
T. Antonucci, J. S. Warmus, J. C. Hodges & D. G. Nickell
- 109 ***In vitro* inhibitory effects of combinations of anti-influenza agents**
L. K. Madren, C. Shipman, Jr & F. G. Hayden
- 114 ***In vitro* antimonyxovirus and anti-human immunodeficiency virus activities of polyoxometalates**
S. Shigeta, S. Mori, J. Watanabe, M. Baba, A. M. Khenkin, C. L. Hill & R. F. Schinazi

Short communication

- 123 **Inhibition by azidothymidine triphosphate of reverse transcriptase from paired AZT-susceptible and -resistant primary isolates of human immunodeficiency virus type 1**
S. W. Cox, G. Corrigan & S. Palmer

Volume 6, Number 3, 1995

- 127 **The intracellular formation of a mononucleotide of the anti-influenza agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896)**
G. M. Birch, J. M. Colacino, W. J. Ehlhardt & J. Balzarini
- 138 **Stereochemical aspects of the anti-HCMV activity of cytidine nucleoside analogues**
T. S. Mansour, A. R. Cimpoia, H. Jin, P. J. Hunter, C. A. Evans, H. L. A. Tse, J. W. Gillard, A. D. Borthwick, D. J. Knight & J. A. V. Coates
- 143 **Synergistic inhibition of human immunodeficiency virus type 1 *in vitro* by 6-0-butanoylcastanospermine (MDL 28574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase**
D. L. Taylor, T. M. Brennan, C. G. Bridges, M. S. Kang & A. S. Tyms
- 153 **Efficacy and toxicity of long-term administration of 2',3'-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model**
G. Brandi, A. Casabianca, G. F. Schiavano, L. Rossi, A. Fraternali, A. Albano & M. Magnani
- 162 **Synthesis and antiviral evaluation of fluorinated dipyrroliodiazepinones and dipyrroliodiazepines (nevirapine derivatives)**
B. P. Boyode, M. Sinet, A. Farese, M.-A. Forestier-Roux, R. Condom, I.A. Ayi, A. Kim, C. Moog & R. Guedj

- 169 **Oxathiin carboxanilide derivatives: a class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs**
J. Balzarini, H. Jonckheere, W. A. Harrison, D. C. Dao, J. Anné, E. De Clercq & A. Karlsson
- 179 **Anti-HIV and anti-HCMV activities of new aurintricarboxylic acid analogues**
M. Cushman, P. Wang, D. Reymen, J. Esté, M. Witvrouw, J. Neyts & E. De Clercq

Short communication

- 187 **Inhibition of the production of HIV-1 from chronically infected H9 cells by metal compounds and their complexes with L-cysteine or N-acetyl-L-cysteine**
N. Mahmood, A. Burke, S. Hussain, R. M. Anner & B. M. Anner

Volume 6, Number 4, 1995

Review

- 191 **Progress in the clinical management of herpesvirus infections**
P. D. Griffiths
- 210 **The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1**
H. J. Field & A. M. Thackray
- 217 **Kinetic interaction of the diphosphates of 9-(2-phosphorylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α , β and γ**
J. M. Cherrington, S. J. W. Allen, N. Bischofberger & M. S. Chen
- 222 **Host cell dependence of human immunodeficiency virus type-1 drug resistance profiles and tissue culture selection patterns**
H. Salomon, Z. Gu, Q. Gao, K. Nagai, J. Hiscott & M. A. Wainberg
- 230 **Lymphatic targeting of anti-HIV nucleosides: distribution of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZdU) after administration of dipalmitoylphosphatidyl prodrugs to mice**
K. K. Manouilov, I. I. Fedorov, F. D. Boudinot, C. A. White, L. P. Kotra, R. F. Schinazi, Chung II Hong & Chung K. Chu
- 239 **Inhibition of herpes simplex virus type-1 multiplication by meliacine, a peptide of plant origin**
S. M. Villamil, L. E. Alché & C. E. Coto
- 245 **Novel azolylalkyloxy compounds with antipicornaviral activity**
M. D. Abel, A. D. Cameron, C. M. Ha, C. A. Koski, H. T. Luu, R. G. Micetich, D. Q. Nguyen, M. L. Tempest & M. Daneshmand

- 255 **Design and synthesis of a quenched fluorogenic peptide substrate for human cytomegalovirus proteinase**
B. K. Handa, E. Keech, E. A. Conway, A. Broadhurst & A. Ritchie
- 262 **2'-Deoxyuridines with a 5-heteroaromatic substituent: synthesis and biological evaluation**
I. Luyten, L. Jie, A. Van Aerschoot, C. Pannecouque, P. Wigerinck, J. Rozenki, C. Hendrix, C. Wang, L. Wiebe, J. Balzarini, E. De Clercq & P. Herdewijn
- 271 **Sulfated alkyl oligosaccharides inhibit human immunodeficiency virus *in vitro* and provide sustained drug levels in mammals**
H. Nakashima, K. Inazawa, K. Ichijima, M. Ito, N. Ikushima, T. Shoji, K. Katsuraya, T. Uryu, N. Yamamoto, A. S. Juodawakis & R. F. Schinazi

Volume 6, Number 5, 1995

- 281 **Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene**
H. C. Chiou, K. Kumura, A. Hu, K. M. Kerns & D. M. Coen
- 289 **Synthesis and anti-herpes activity of a series of indolizines**
C. Foster, M. Ritchie, D. L. Selwood & W. Snowden
- 298 ***In vitro* evaluation of the anti-picornavirus activities of new synthetic flavonoids**
N. Desideri, C. Conti, I. Sestili, P. Tomao, M. L. Stein & N. Orsi
- 307 **Basis of relative insensitivity of HIV-infected JM cells to AZT**
R. D. Snyder, T. Brennan, D. L. Taylor & A. S. Tys
- 312 **Inhibition of HIV-1 and LP-BM5 replication in macrophages by dideoxycytidine and dideoxycytidine 5'-triphosphate**
M. Magnani, A. Casabianca, L. Rossi, A. Fraternali, G. Brandi, L. Silvotti & G. Piedimonte
- 320 **Synthesis and *in vitro* antiviral properties of amphiphilic dinucleoside phosphate derivatives of 2',3'-dideoxycytidine (ddC)**
H. Schott, M. P. Häussler, P. Gowland, A. Bender, H. von Briesen & R. A. Schwendener
- 327 **Potent and orally bioavailable HIV-1 proteinase inhibitors containing the 2-aminobenzylstatine moiety**
A. Billich, D. Scholz, B. Charpiot, H. Gstach, P. Lehr, P. Peichl & B. Rosenwirth
- 337 **Dimeric macrocyclic polyamines with potent inhibitory activity against human immunodeficiency virus**
Y. Inouye, T. Kanamori, M. Sugiyama, T. Yoshida, T. Koike, M. Shionoya, K. Enomoto, K. Suehiro & E. Kimura

Volume 6, Number 6, 1995

- 345 **The effect of absolute configuration on the anti-HIV and anti-HBV activity of nucleoside analogues**
P. A. Furman, J. E. Wilson, J. E. Reardon & G. R. Painter
- 356 **A comparative study of 5-ethyl-2'-deoxyuridine and selected lipophilic 5,6-dihydro double/triple prodrugs**
A. M. Cheraghali, R. Kumar, K. W. Morin, E. De Clercq, E. E. Knaus & L. I. Wiebe
- 365 **Synthesis and anti-HIV-1 activity of [1-[2',5'-Bis-O-(*tert*-butyldimethylsilyl)- β -L-ribofuranosyl]thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (L-TSAO-T), the L-enantiomer of the highly specific HIV-1 reverse transcriptase inhibitor TSAO-T**
S. T. Ingate, M.-J. Camarasa, E. De Clercq & J. Balzarini
- 371 **Antiviral activity of bicyclic pyrimidine nucleosides**
D. Loakes, D. M. Brown, N. Mahmood, J. Balzarini & E. De Clercq
- 379 **Zalcitabine (ddC) phosphorylation and drug interactions**
G.J. Veal, M.G. Barry & D.J. Back
- 385 **Effects of plant-derived polysaccharides on murine cytomegalovirus and encephalomyocarditis virus infections in mice**
D. F. Smee, & A. J. Verbiscar
- 391 **Antiviral activities of peptides with sequences related to the cytoplasmic domain of the respiratory syncytial virus glycoproteins**
C. Ryan, J. Mo & M. Schlesinger

Indexes

- 399 **Subject Index**
- 401 **Author Index**
- 403 **Referees**